{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:13:34Z","timestamp":1790730814651,"version":"4.1.0"},"reference-count":47,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Natural Sciences and Engineering Research Council of Canada","award":["RGPIN-2019-05284"],"award-info":[{"award-number":["RGPIN-2019-05284"]}]},{"name":"Natural Sciences and Engineering Research Council of Canada","award":["NFRFT-2022-00269"],"award-info":[{"award-number":["NFRFT-2022-00269"]}]},{"name":"New Frontiers in Research Fund\u2014Transformation","award":["RGPIN-2019-05284"],"award-info":[{"award-number":["RGPIN-2019-05284"]}]},{"name":"New Frontiers in Research Fund\u2014Transformation","award":["NFRFT-2022-00269"],"award-info":[{"award-number":["NFRFT-2022-00269"]}]},{"name":"Abdenour Nabid scholarship from the Faculty of Medicine and Health Sciences, Universit\u00e9 de Sherbrooke","award":["RGPIN-2019-05284"],"award-info":[{"award-number":["RGPIN-2019-05284"]}]},{"name":"Abdenour Nabid scholarship from the Faculty of Medicine and Health Sciences, Universit\u00e9 de Sherbrooke","award":["NFRFT-2022-00269"],"award-info":[{"award-number":["NFRFT-2022-00269"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Glioblastoma multiforme (GBM) remains one of the most aggressive and treatment-resistant brain tumors, with poor prognosis and limited therapeutic options. Background\/Objectives: Integrin \u03b1v\u03b23, a cell surface receptor overexpressed in GBM, specifically binds to cyclic arginine-glycine-aspartate-D-phenylalanine-lysine (c(RGDfK)) motif, making it a valuable target for tumor-specific delivery and PET imaging. This study explores a novel radiotheranostic agent, [64Cu]Cu-NOTA-TP-c(RGDfK), which combines the imaging and therapeutic capabilities of copper-64 (64Cu) and the cytotoxic activity of a terpyridine-platinum (TP) complex, conjugated to c(RGDfK). Methods: A robust protocol was developed for the small-scale preparation of NOTA-TP-c(RGDfK). Comparative cellular studies were conducted using U87 MG glioblastoma (GBM) cells and SVG p12 human astrocytes to evaluate the performance of [64Cu]Cu-NOTA-TP-c(RGDfK) relative to [64Cu]Cu-NOTA-c(RGDfK), [64Cu]Cu-NOTA-TP, natCu-NOTA-TP-c(RGDfK), cisplatin, and temozolomide. Results: 64Cu-radiolabeling of NOTA-TP-c(RGDfK) was achieved with &gt;99% radiochemical purity, and competition assays confirmed high binding affinity to integrin \u03b1v\u03b23 (IC50 = 16 \u00b1 8 nM). Cellular uptake, internalization, and retention studies demonstrated significantly higher accumulation of [64Cu]Cu-NOTA-TP-c(RGDfK) in U87 MG cells compared to control compounds, with 38.8 \u00b1 1.8% uptake and 28.0 \u00b1 1.0% internalization at 24 h. Nuclear localization (6.0 \u00b1 0.5%) and stable intracellular retention further support its therapeutic potential for inducing localized DNA damage. Importantly, [64Cu]Cu-NOTA-TP-c(RGDfK) exhibited the highest cytotoxicity in U87 MG cells (IC50 = 10 \u00b1 2 nM at 48 h), while maintaining minimal toxicity in normal SVG p12 astrocytes. Conclusions: These results highlight [64Cu]Cu-NOTA-TP-c(RGDfK) as a promising targeted radiotheranostic agent for GBM, warranting further preclinical development<\/jats:p>","DOI":"10.3390\/brainsci15080844","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T09:56:42Z","timestamp":1754647002000},"page":"844","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Targeted Radiotheranostic Agent for Glioblastoma: [64Cu]Cu-NOTA-TP-c(RGDfK)"],"prefix":"10.3390","volume":"15","author":[{"given":"Alireza","family":"Mirzaei","sequence":"first","affiliation":[{"name":"Department of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Ait-Mohand","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prenitha Mercy","family":"Ignatius Arokia Doss","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2394-7446","authenticated-orcid":false,"given":"\u00c9tienne","family":"Rousseau","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada"},{"name":"Sherbrooke Molecular Imaging Center (CIMS), Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CRCHUS), 3001, 12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada"},{"name":"Institut de Recherche sur le Cancer de l\u2019Universit\u00e9 de Sherbrooke (IRCUS), Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0319-4512","authenticated-orcid":false,"given":"Brigitte","family":"Gu\u00e9rin","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada"},{"name":"Sherbrooke Molecular Imaging Center (CIMS), Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CRCHUS), 3001, 12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada"},{"name":"Institut de Recherche sur le Cancer de l\u2019Universit\u00e9 de Sherbrooke (IRCUS), Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"ref_1","first-page":"1902971","article-title":"Advances in the Knowledge of the Molecular Biology","volume":"7","author":"Medina","year":"2020","journal-title":"Adv. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"D\u00e9ry, L., Charest, G., Gu\u00e9rin, B., Akbari, M., and Fortin, D. (2021). Chemoattraction of Neoplastic Glial Cells with CXCL10, CCL2 and CCL11 as a Paradigm for a Promising Therapeutic Approach for Primary Brain Tumors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212150"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nou223","article-title":"CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007\u20132011","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro-Oncology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Mathew, E.N., Berry, B.C., Yang, H.W., Carroll, R.S., and Johnson, M.D. (2022). Delivering Therapeutics to Glioblastoma: Overcoming Biological Constraints. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031711"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4748","DOI":"10.1016\/j.apsb.2023.09.009","article-title":"Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood\u2013brain barrier and exhibits potent activity against glioblastoma","volume":"13","author":"Liu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"105780","DOI":"10.1016\/j.phrs.2021.105780","article-title":"Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance","volume":"171","author":"Wu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"L12","DOI":"10.1186\/2193-1801-4-S1-L12","article-title":"The role of integrins in glioma biology and anti-glioma therapies","volume":"4","author":"Roth","year":"2015","journal-title":"SpringerPlus"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Takada, Y., Ye, X., and Simon, S. (2007). The integrins. Genome Biol., 8.","DOI":"10.1186\/gb-2007-8-5-215"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Echavidre, W., Picco, V., Faraggi, M., and Montemagno, C. (2022). Integrin-\u03b1v\u03b23 as a Therapeutic Target in Glioblastoma: Back to the Future?. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14051053"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s41048-016-0021-8","article-title":"Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging","volume":"2","author":"Shi","year":"2016","journal-title":"Biophys. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1061186X.2018.1455841","article-title":"RGD peptide-based non-viral gene delivery vectors targeting integrin \u03b1v\u03b23 for cancer therapy","volume":"27","author":"Fu","year":"2019","journal-title":"J. Drug Target."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Haubner, R., Weber, W.A., Beer, A.J., Vabuliene, E., Reim, D., Sarbia, M., Becker, K.-F., Goebel, M., Hein, R., and Wester, H.-J. (2005). Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020070"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1021\/bc034170n","article-title":"[18F]Galacto-RGD: Synthesis, Radiolabeling, Metabolic Stability, and Radiation Dose Estimates","volume":"15","author":"Haubner","year":"2004","journal-title":"Bioconjug. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Novy, Z., Stepankova, J., Hola, M., Flasarova, D., Popper, M., and Petrik, M. (2019). Preclinical Evaluation of Radiolabeled Peptides for PET Imaging of Glioblastoma Multiforme. Molecules, 24.","DOI":"10.3390\/molecules24132496"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1021\/mp5003224","article-title":"68Ga-PRGD2 PET\/CT in the Evaluation of Glioma: A Prospective Study","volume":"11","author":"Li","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-02041-6","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"113757","DOI":"10.1016\/j.jconrel.2025.113757","article-title":"Development of radioligands with an albumin-binding moiety of 4-(P-Iodophenyl) butyric acid for theranostic applications","volume":"382","author":"Meng","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_19","first-page":"5303","article-title":"New Therapeutic Possibilities of Combined Treatment of Radiotherapy with Oxaliplatin and its Liposomal Formulation, Lipoxal\u2122, in Rectal Cancer Using Xenograft in Nude Mice","volume":"34","author":"Tippayamontri","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_20","first-page":"4395","article-title":"Synergism in concomitant chemoradiotherapy of cisplatin and oxaliplatin and their liposomal formulation in the human colorectal cancer HCT116 model","volume":"32","author":"Tippayamontri","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_21","first-page":"3005","article-title":"Efficacy of cisplatin and Lipoplatin\u2122 in combined treatment with radiation of a colorectal tumor in nude mouse","volume":"33","author":"Tippayamontri","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncponc0714","article-title":"The concurrent chemoradiation paradigm--general principles","volume":"4","author":"Seiwert","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s10637-010-9494-3","article-title":"Cellular Uptake and Cytoplasm\/DNA Distribution of Cisplatin and Oxaliplatin and Their Liposomal Formulation in Human Colorectal Cancer Cell HCT116","volume":"29","author":"Tippayamontri","year":"2011","journal-title":"Investig. New Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.21037\/atm.2018.05.10","article-title":"Optimal regimen of cisplatin in squamous cell carcinoma of head and neck yet to be determined","volume":"6","author":"Le","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7848","DOI":"10.1039\/C8DT90088D","article-title":"The side effects of platinum-based chemotherapy drugs: A review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton trans."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1124\/pr.111.005637","article-title":"Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes","volume":"64","author":"Shen","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1039\/C4DT02773F","article-title":"The synthesis, characterisation and cytotoxicity of bisintercalating (2,2\u2032:6\u2032,2\u2032-terpyridine) platinum(ii) complexes","volume":"44","author":"Harper","year":"2015","journal-title":"Dalton Trans."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2147\/DDDT.S119488","article-title":"Metal complexes in cancer therapy\u2014An update from drug design perspective","volume":"3","author":"Ndagi","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1039\/C4DT02910K","article-title":"Syntheses of polypyridyl metal complexes and studies of their interaction with quadruplex DNA","volume":"44","author":"Stafford","year":"2014","journal-title":"Dalton Trans."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10534-018-0155-x","article-title":"New platinum(II) and palladium(II) complexes with substituted terpyridine ligands: Synthesis and characterization, cytotoxicity and reactivity towards biomolecules","volume":"32","author":"Marzo","year":"2019","journal-title":"Biometals"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1002\/anie.200906363","article-title":"Interaction of metal complexes with G-quadruplex DNA","volume":"49","author":"Georgiades","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41557-020-0506-4","article-title":"Single-molecule visualization of DNA G-quadruplex formation in live cells","volume":"12","author":"Ponjavic","year":"2020","journal-title":"Nat. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1039\/b904599f","article-title":"Exclusive platination of loop adenines in the human telomeric G-quadruplex","volume":"7","author":"Bertrand","year":"2009","journal-title":"Org. Biomol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6765","DOI":"10.1021\/acs.jmedchem.1c00039","article-title":"High cytotoxic effect by combining copper-64 with a NOTA-terpyridine platinum conjugate","volume":"64","author":"Khosravifarsani","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Khosravifarsani, M., Ait-Mohand, S., Paquette, B., Sanche, L., and Gu\u00e9rin, B. (2021). Design, Synthesis, and Cytotoxicity Assessment of [64Cu]Cu-NOTA-Terpyridine Platinum Conjugate: A Novel Chemoradiotherapeutic Agent with Flexible Linker. Nanomaterials, 11.","DOI":"10.3390\/nano11092154"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Khosravifarsani, M., Ait-Mohand, S., Paquette, B., Sanche, L., and Gu\u00e9rin, B. (2022). In vivo behavior of [64Cu]NOTA-terpyridine platinum, a novel chemo-radio-theranostic agent for imaging, and therapy of colorectal cancer. Front. Med., 9.","DOI":"10.3389\/fmed.2022.975213"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10989-010-9238-4","article-title":"Investigation of the Best Conditions to Obtain c(RGDfK) Peptide on Solid Phase","volume":"17","year":"2011","journal-title":"Int. J. Pept. Res. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1021\/ol902601x","article-title":"Total solid-phase synthesis of NOTA-functionalized peptides for PET imaging","volume":"12","author":"Tremblay","year":"2010","journal-title":"Org Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/ejic.201601094","article-title":"Functionalization of Ruthenium(II) Terpyridine Complexes with Cyclic RGD Peptides to Target Integrin Receptors in Cancer Cells","volume":"2017","author":"Hahn","year":"2016","journal-title":"Eur. J. Inorg. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2014.11.003","article-title":"Use of the viability reagent PrestoBlue in comparison with alamarBlue and MTT to assess the viability of human corneal epithelial cells","volume":"71","author":"Xu","year":"2015","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lo, W.-L., Lo, S.-W., Chen, S.-J., Chen, M.-W., Huang, Y.-R., Chen, L.-C., Chang, C.-H., and Li, M.-H. (2021). Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115459"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"15148","DOI":"10.1021\/acsami.5b03866","article-title":"Dual-Peptide-Functionalized Albumin-Based Nanoparticles with pH-Dependent Self-Assembly Behavior for Drug Delivery","volume":"7","author":"Chen","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/acs.molpharmaceut.1c00046","article-title":"The Uniqueness of Albumin as a Carrier in Nanodrug Delivery","volume":"18","author":"Spada","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1476-4598-9-84","article-title":"Intracellular targets of RGDS peptide in melanoma cells","volume":"22","author":"Aguzzi","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11060-010-0196-7","article-title":"Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: The concept of divergent targeting","volume":"100","author":"Watt","year":"2010","journal-title":"J. Neurooncol."},{"key":"ref_46","first-page":"1707","article-title":"microPET imaging of glioma integrin \u03b1v\u03b23 expression using 64Cu-labeled tetrameric RGD peptide","volume":"46","author":"Wu","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_47","first-page":"1776","article-title":"Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression","volume":"45","author":"Chen","year":"2004","journal-title":"J. Nucl. Med."}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/15\/8\/844\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:25:48Z","timestamp":1760034348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/15\/8\/844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["brainsci15080844"],"URL":"https:\/\/doi.org\/10.3390\/brainsci15080844","relation":{},"ISSN":["2076-3425"],"issn-type":[{"value":"2076-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]}}}